Aardvark Therapeutics Inc (AARD) Stock Analysis
Verdict: AVOID
Pre-revenue ARD-101 trials face imminent cash depletion within 10 months and analyst downgrades, making dilution risk paramount at $6.81.
Investment score: 28/100
Analysis as of
Is Aardvark Therapeutics Inc stock worth reviewing? AI model thesis
The AI model rates AARD as an AVOID due to high dilution risk from a 10-month cash runway, persistent analyst downgrades, and a share price trading well above consensus targets.
7-factor investment score
- Valuation: 25/100 (weight 20%)
- Financial Health: 15/100 (weight 15%)
- Technical Momentum: 30/100 (weight 15%)
- Earnings Quality: 35/100 (weight 15%)
- Insider Sentiment: 55/100 (weight 10%)
- Analyst Consensus: 25/100 (weight 10%)
- Risk-Adjusted Return: 20/100 (weight 15%)
Aardvark Therapeutics Inc opportunities and risks
What speaks for AARD
- Phase III trial success for ARD-101 in Prader-Willi Syndrome
What speaks against AARD
- Imminent equity dilution and capital raise pressure
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| AARD | n/a | 0.0x | n/a | 0.0% | 0.0% | -46.6% |
| ANTX | n/a | 0.0x | n/a | 0.0% | 0.0% | -15.4% |
| GRIN.CN | n/a | 2.8x | 81.3x | 45.0% | -6.4% | -1.3% |
| LENZ | n/a | 7.0x | n/a | 90.1% | -586.7% | -76.3% |
| NRXP | n/a | 17.6x | n/a | 32.7% | -691.8% | -34.6% |
| Peer median | n/a | 4.9x | n/a | 38.8% | -296.6% | -25.0% |
Frequently asked questions about Aardvark Therapeutics Inc (AARD)
Is AARD stock a good investment?
The cached TradeMates AI model rates Aardvark Therapeutics Inc as AVOID with an investment score of 28/100. The AI model rates AARD as an AVOID due to high dilution risk from a 10-month cash runway, persistent analyst downgrades, and a share price trading well above consensus targets. This is algorithmic model output, not personal investment advice.
Is AARD stock a buy?
The TradeMates model verdict for AARD is AVOID with an investment score of 28/100. Treat this as a model signal to review, not a personal buy recommendation.